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Eag

:   ether‐à‐go‐go channel

Elk

:   ether‐à‐go‐go‐gene‐like channel

hERG

:   human ether‐à‐go‐go‐related gene channel 1

Erg

:   ether‐à‐go‐go‐related gene channel

LQT

:   long QT

MD

:   molecular dynamics

RMSD

:   root‐mean‐square deviation

What is already known {#bph14693-sec-1001}
=====================

Drug‐induced inhibition of K~v~11.1 (hERG) is a frequent cause of sudden death in humans.It is not known whether closely related K~v~12 channels are also sensitive to drug‐dependent inhibition.

What this study adds {#bph14693-sec-1002}
====================

Low quinine sensitivity, affinity, and characteristics of inhibition of K~v~12.1 channels are determined by H462.Drug sensitivity of K~v~11.1 and K~v~12.1 is different but determined by homologous amino acid positions.

What is the clinical significance {#bph14693-sec-1003}
=================================

Drug‐binding pockets are not conserved in Eag superfamily members, but channel architecture is similar.Our findings facilitate the understanding of the arrhythmogenic actions of quinine.

1. INTRODUCTION {#bph14693-sec-0007}
===============

The ether‐à‐go‐go (Eag) superfamily of K~v~ channels comprises the three conserved families of Eag (K~v~10), ether‐à‐go‐go‐related gene (Erg; K~v~11), and ether‐à‐go‐go‐gene‐like (Elk; K~v~12) channels. These channels give rise to voltage‐dependent K^+^ currents in many cell types (Bauer & Schwarz, [2001](#bph14693-bib-0003){ref-type="ref"}; Bauer & Schwarz, [2018](#bph14693-bib-0004){ref-type="ref"}). The best characterised member, [K~v~11.1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=572&familyId=81&familyType=IC) (termed [hERG](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=572&familyId=81&familyType=IC) for the human isoform), engenders rapidly activating K^+^ current *I* ~Kr~ responsible for membrane repolarisation in cardiac myocytes (Sanguinetti, Jiang, Curran, & Keating, [1995](#bph14693-bib-0050){ref-type="ref"}). As *I* ~Kr~ determines duration and end of heart action potentials, loss of K~v~11.1 function constitutes a frequent cause of cardiac dysfunction in humans (Curran et al., [1995](#bph14693-bib-0010){ref-type="ref"}; Keating & Sanguinetti, [2001](#bph14693-bib-0029){ref-type="ref"}; Mitcheson, Chen, Lin, Culberson, & Sanguinetti, [2000](#bph14693-bib-0040){ref-type="ref"}; Sanguinetti et al., [1995](#bph14693-bib-0050){ref-type="ref"}; Trudeau, Warmke, Ganetzky, & Robertson, [1995](#bph14693-bib-0057){ref-type="ref"}). Mutations in [KCNH2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=572&familyId=81&familyType=IC), the gene encoding K~v~11.1, cause congenital long QT (LQT) syndrome‐2 characterised by a prolonged QT interval and polymorphic ventricular arrhythmias (torsade de pointes) that may lead to recurrent syncope or sudden death (Curran et al., [1995](#bph14693-bib-0010){ref-type="ref"}; Sanguinetti et al., [1995](#bph14693-bib-0050){ref-type="ref"}). More common, however, are acquired forms of LQT syndrome through drug‐induced inhibition of K~v~11.1 (Keating & Sanguinetti, [2001](#bph14693-bib-0029){ref-type="ref"}; Roden, [1996](#bph14693-bib-0046){ref-type="ref"}; Sanguinetti et al., [1995](#bph14693-bib-0050){ref-type="ref"}). K~v~11.1 channels are extremely sensitive to a wide variety of drugs including substituted quinolines ([quinidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2342), [quinine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2510), and [chloroquine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535)), antiarrhythmic agents (e.g., MK‐499 and dofetilide), and many other substances (e.g., terfenadine, cisapride, and vesnarinone; Furutani et al., [2011](#bph14693-bib-0018){ref-type="ref"}; Kamiya, Mitcheson, Yasui, Kodama, & Sanguinetti, [2001](#bph14693-bib-0026){ref-type="ref"}; Lees‐Miller, Duan, Teng, & Duff, [2000](#bph14693-bib-0031){ref-type="ref"}; Mitcheson et al., [2000](#bph14693-bib-0040){ref-type="ref"}; Mitcheson et al., [2005](#bph14693-bib-0039){ref-type="ref"}; Sanchez‐Chapula, Ferrer, Navarro‐Polanco, & Sanguinetti, [2003](#bph14693-bib-0048){ref-type="ref"}; Sanchez‐Chapula, Navarro‐Polanco, Culberson, Chen, & Sanguinetti, [2002](#bph14693-bib-0049){ref-type="ref"}). All of these substances may cause undesired prolongation of cardiac action potentials by inhibiting K~v~11.1 (Sanguinetti et al., [1995](#bph14693-bib-0050){ref-type="ref"}). The high susceptibility of human K~v~11.1 to these structurally divergent drugs is governed by amino acids facing the channel\'s central cavity to form hydrophobic‐binding pockets (Wang & MacKinnon, [2017](#bph14693-bib-0060){ref-type="ref"}). Mutagenesis studies have shown that amino acids in the inner pore helix (threonine 623), selectivity filter (serine 624 and valine 625), and tyrosine 652/phenylalanine 656 of the sixth transmembrane segment (S6) determine the susceptibility of drug‐induced inhibition in K~v~11.1 (Mitcheson et al., [2000](#bph14693-bib-0040){ref-type="ref"}; Sanchez‐Chapula et al., [2002](#bph14693-bib-0049){ref-type="ref"}; Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}; Wang & MacKinnon, [2017](#bph14693-bib-0060){ref-type="ref"}). Some of these residues are involved in drug binding (threonine 623, serine 624, tyrosine 652, and phenylalanine 656; Wang & MacKinnon, [2017](#bph14693-bib-0060){ref-type="ref"}), whereas others (e.g., valine 625 and also asparagine 588, serine 631, and serine 620) have been shown to control drug sensitivity through contributing to channel inactivation that is necessary for K~v~11.1 inhibition through many high‐affinity blockers (Ficker, Jarolimek, & Brown, [2001](#bph14693-bib-0016){ref-type="ref"}; Ficker, Jarolimek, Kiehn, Baumann, & Brown, [1998](#bph14693-bib-0017){ref-type="ref"}; Kamiya, Niwa, Mitcheson, & Sanguinetti, [2006](#bph14693-bib-0027){ref-type="ref"}; Perrin, Kuchel, Campbell, & Vandenberg, [2008](#bph14693-bib-0045){ref-type="ref"}; Wu, Gardner, & Sanguinetti, [2015](#bph14693-bib-0061){ref-type="ref"}). Further, phenylalanine 557 located in the S5 helix is involved in binding of some drugs (Helliwell et al., [2018](#bph14693-bib-0021){ref-type="ref"}; Saxena et al., [2016](#bph14693-bib-0052){ref-type="ref"}). Most of these residues are conserved in K~v~10 channels, and accordingly, the [K~v~10.1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=570) isoform exhibits similarly high sensitivity to some substances (Schonherr, Gessner, Lober, & Heinemann, [2002](#bph14693-bib-0053){ref-type="ref"}). However, [K~v~10.2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=571) is significantly less susceptible to drug‐induced inhibition, indicating that additional motifs might contribute to drug binding in certain members of the superfamily (Chen, Seebohm, & Sanguinetti, [2002](#bph14693-bib-0009){ref-type="ref"}; Gessner, Zacharias, Bechstedt, Schonherr, & Heinemann, [2004](#bph14693-bib-0019){ref-type="ref"}; Schonherr et al., [2002](#bph14693-bib-0053){ref-type="ref"}). In fact, it has been shown that high‐affinity blockers of K~v~11.1 are less effective on K~v~10 channels, as these isoforms do not inactivate. This suggests that conformational reorientation of relevant residues associated with inactivation that are necessary for inhibition of K~V~11.1 is absent in K~v~10 channels (Chen et al., [2002](#bph14693-bib-0009){ref-type="ref"}; Ficker et al., [1998](#bph14693-bib-0017){ref-type="ref"}; Ficker et al., [2001](#bph14693-bib-0016){ref-type="ref"}).

In contrast to K~v~10 and K~v~11, only little information is available on the three members of the K~v~12 (Elk) family predominantly expressed in neurons (Engeland, Neu, Ludwig, Roeper, & Pongs, [1998](#bph14693-bib-0015){ref-type="ref"}; Miyake, Mochizuki, Yokoi, Kohda, & Furuichi, [1999](#bph14693-bib-0041){ref-type="ref"}; Saganich, Machado, & Rudy, [2001](#bph14693-bib-0047){ref-type="ref"}; Shi et al., [1998](#bph14693-bib-0054){ref-type="ref"}; Trudeau, Titus, Branchaw, Ganetzky, & Robertson, [1999](#bph14693-bib-0056){ref-type="ref"}; Zou et al., [2003](#bph14693-bib-0063){ref-type="ref"}). [K~v~12.2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=576) regulates excitability of hippocampal neurons (Zhang et al., [2010](#bph14693-bib-0062){ref-type="ref"}), but no physiological role has been assigned to [K~v~12.1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=575) and [K~v~12.3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=577) channels yet. Recent studies provided significant insight into functional characteristics of K~v~12.1 (Dai & Zagotta, [2017](#bph14693-bib-0011){ref-type="ref"}; Dierich, Evers, Wilke, & Leitner, [2018](#bph14693-bib-0013){ref-type="ref"}; Dierich & Leitner, [2018](#bph14693-bib-0014){ref-type="ref"}; Kazmierczak et al., [2013](#bph14693-bib-0028){ref-type="ref"}; Li et al., [2015](#bph14693-bib-0035){ref-type="ref"}), but it is unknown whether K~v~12 channels are equipped with a high affinity drug‐binding pocket as K~v~10.1 and K~v~11.1.

We analysed the sensitivity of human K~v~12.1 to quinine, a substituted quinoline that blocks K~v~11.1 channels at low micromolar concentrations (Gessner et al., [2004](#bph14693-bib-0019){ref-type="ref"}; Mitcheson et al., [2000](#bph14693-bib-0040){ref-type="ref"}; Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}; Schonherr et al., [2002](#bph14693-bib-0053){ref-type="ref"}). Quinine also inhibited recombinant K~v~12.1 channels, but their sensitivity was 10‐fold lower than that of K~v~11.1. Contrary to K~v~11.1, quinine‐dependent block of K~v~12.1 was largely voltage‐independent and the substance induced channel opening at more depolarised membrane potentials. Mutagenesis of histidine at position 462 (H462) into the homologous tyrosine (Y652) of K~v~11.1 conferred K~v~11.1‐like quinine sensitivity to K~v~12.1(H462Y) channels. Molecular modelling analyses demonstrated that the low quinine sensitivity of K~v~12.1 was determined by only weak interactions of quinine with H462 in the central cavity, whereas more favourable interactions facilitated higher quinine sensitivity of K~v~12.1(H462Y) and closely related K~v~11.1. Our data showed that the drug‐binding pocket in the central cavity is not conserved in the Eag superfamily, although the general architecture of these channels is apparently similar. Our findings highlight functional and pharmacological diversity within this group of evolutionary conserved K^+^ channels.

2. METHODS {#bph14693-sec-0008}
==========

2.1. Cell culture, transient transfection, and mutagenesis {#bph14693-sec-0009}
----------------------------------------------------------

CHO dhFR^−^ cells (ATCC Cat\# CRL‐9096, RRID:CVCL_1977) were maintained as previously reported (Leitner et al., [2016](#bph14693-bib-0034){ref-type="ref"}). In brief, cells were maintained in MEM alpha medium (with 10% fetal calf serum and 1% pen/strep; all Invitrogen GmbH, Darmstadt, Germany) at 5% CO~2~ and 37°C in a humidified atmosphere. Transient transfection of cultured CHO cells was performed using jetPEI (Polyplus Transfection, Illkirch, France). The following vectors for ion channel expression were used: K~v~11.1 (Erg1)--pcDNA3.1 (gene: rat *Kcnh2*; UniProt accession number: O08962; [UniProt](http://www.uniprot.org/), RRID:SCR_002380), K~v~12.1 (Elk1)--pcDNA3.1--IRES--eGFP (human [KCNH8](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=575); Q96L42), and pEGFP--C1 (transfection control; Addgene, Teddington, UK). An amino acid exchange (H462Y) was introduced into K~v~12.1 with the QuikChangeII XL site‐directed mutagenesis kit (Stratagene, Santa Clara, CA). Site‐directed mutagenesis was confirmed by sequencing prior to the experiments (Microsynth SEQLAB, Göttingen, Germany).

2.2. Electrophysiological recordings {#bph14693-sec-0010}
------------------------------------

Whole‐cell patch clamp recordings were performed at room temperature (22--25°C) with an HEKA EPC10 USB patch clamp amplifier controlled by PatchMaster software (HEKA, Lambrecht, Germany; Patchmaster, RRID:SCR_000034). Voltage clamp recordings were low‐pass filtered at 2 kHz and sampled at 5 kHz. The series resistance (*R* ~*s*~) was kept below 6 MΩ, and *R* ~*s*~ was compensated throughout the recordings (80--90%; Dierich & Leitner, [2018](#bph14693-bib-0014){ref-type="ref"}; Leitner, Halaszovich, & Oliver, [2011](#bph14693-bib-0033){ref-type="ref"}). All voltage protocols are indicated in the figures; dashed lines highlight zero current. Borosilicate glass patch pipettes (Sutter Instrument Company, Novato, CA) had an open‐pipette resistance of 2--3 MΩ after backfilling with intracellular solution containing (in mM) 135 KCl, 2.41 CaCl~2~ (100‐nM free Ca^2+^), 3.5 MgCl~2~, 5 HEPES, 5 EGTA, 2.5 Na~2~ATP, and 0.1 Na~3~GTP, pH 7.3 (with KOH), 290--295 mOsm·kg^−1^. The extracellular solution contained (in mM) 144 NaCl, 5.8 KCl, 1.3 CaCl~2~, 0.9 MgCl~2~, 0.7 NaH~2~PO~4~, 10 HEPES, and 5.6 [d]{.smallcaps}‐glucose, pH 7.4 (with NaOH), 305--310 mOsm·kg^−1^. Liquid junction potentials were not compensated (approximately −4 mV).

2.3. Analysis of electrophysiological recordings {#bph14693-sec-0011}
------------------------------------------------

Patch clamp recordings were analysed with IgorPro (Wavemetrics, Lake Oswego, OR; IGOR Pro, RRID:SCR_000325) and the PatchMaster (HEKA) software. Voltage‐dependence of activation was derived from tail current amplitudes using voltage protocols indicated: Tail currents were fitted with a two‐state Boltzmann function with *I* = *I* ~min~ + (*I* ~max~ − *I* ~min~)∕(1 *+* exp((*V* − *V* ~*h*~)∕*s*)), where *I* is the current, *V* is the membrane voltage, *V* ~*h*~ is the voltage at half‐maximal activation, and *s* describes the slope of the curve (*s* is presented as positive values to describe the slope of voltage‐dependent channel activation; Leitner et al., [2012](#bph14693-bib-0032){ref-type="ref"}). Results are shown as conductance--voltage curves, obtained by normalising to (*I* ~max~ − *I* ~min~), obtained from fits to data of individual experiments. For dose--response relationships, currents were normalised to baseline and were fitted to a Hill equation with $I = I_{b} + \left( {I_{\max} - I_{b}} \right)/\left( {1 + \left( {{IC}_{50}/\left\lbrack S \right\rbrack} \right)^{n_{H}}} \right)$, where *I* is the (normalised) current, *I* ~*b*~ and *I* ~max~ denote minimal and maximal currents, respectively, IC~50~ is the concentration at the half‐maximal effect, \[*S*\] is the drug concentration, and *n* ~H~ is the Hill coefficient. Time constants of activation were derived from mono‐exponential fits to activating current components at indicated potentials (*τ* activation; c.f. Figure [3](#bph14693-fig-0003){ref-type="fig"}e). For presentation, whole‐cell currents were normalised to cell capacitance (current density; pA·pF^−1^) or to baseline current amplitudes (*I*/*I* ~0~; normalised current).

2.4. Data and statistical analysis {#bph14693-sec-0012}
----------------------------------

The data and statistical analysis comply with the recommendations of the *British Journal of Pharmacology* on experimental design and analysis in pharmacology (Curtis et al., [2018](#bph14693-bib-8811){ref-type="ref"}). Isolated cells under investigation were randomly assigned to different treatment groups. Data analysis for experiments presented was performed in a blinded manner. For some experiments, single recordings were normalised to baseline values individually to account for baseline variations between cells. Statistical analysis was performed using Student\'s two‐tailed *t* test/Wilcoxon--Mann--Whitney test, and when appropriate comparisons between multiple groups were performed with ANOVA followed by Dunnett\'s test. Post hoc tests were run only if *F* achieved *P* \< 0.05 and there was no significant variance inhomogeneity. Significance was assigned at *P* ≤ 0.05 (\**P* ≤ 0.05). Data subjected to statistical analysis have *n* over 5 per group, and data are presented as mean ± standard error of the means (SEM). In electrophysiological experiments, *n* represents the number of individual cells and accordingly the number of independent experiments (no pseudo‐replication).

2.5. Molecular modelling {#bph14693-sec-0013}
------------------------

A K~v~12.1 homology model of the pore module (residues S352--Y477) in the open/inactive conformation was built using the programme modeller 9v.17 (Webb & Sali, [2016](#bph14693-bib-8861){ref-type="ref"}, RRID:SCR_008395) based on the cryo‐EM structure of the hERG (human K~v~11.1) channel (pdb identifier: 5VA1, 3.7 Å resolution; Wang & MacKinnon, [2017](#bph14693-bib-0060){ref-type="ref"}). The sequence identity between target and template is 61% (sequence similarity: 76%). Docking studies were carried out with the Genetic Optimization for Ligand Docking program, version 5.6.2 (GOLD, Jones, Willett, Glen, Leach, & Taylor, [1997](#bph14693-bib-0025){ref-type="ref"}). The "chemscore" fitness scoring function was used, and all residues within 12 Å of residue H462 in K~v~12.1 were defined as binding site. The Chemscore.DG scoring function was used to estimate free energies of binding. Side chains of residues H462 and F466 from all four domains were set as flexible. The pKa of H462 is calculated to be 3.13 (PROPKA; Olsson, Sondergaard, Rostkowski, & Jensen, [2011](#bph14693-bib-0042){ref-type="ref"}), indicating a hydrogen atom on the δ nitrogen. The other two tautomers were considered in docking as well; however, similar binding modes/poses were obtained. For molecular dynamics (MD) system setups and ligand parametrisation (Vanommeslaeghe et al., [2010](#bph14693-bib-0058){ref-type="ref"}), the CHARMM‐GUI (Jo, Kim, Iyer, & Im, [2008](#bph14693-bib-0024){ref-type="ref"}; CHARMM, RRID:SCR_014892) was used. The quinine molecule was protonated at the tertiary N (pKa value of the quinolone group: 9.7, O\'Neil, [2013](#bph14693-bib-0043){ref-type="ref"}). Protein--ligand complexes obtained from docking were embedded in a 1‐palmitoyl‐2‐oleoyl‐*sn*‐glycero‐3‐phosphocholine bilayer and solvated with TIP3P waters. K^+^ ions were placed in the selectivity filter at sites S0, S2, and S4, with water molecules at sites S1 and S3 and 0.15‐M KCl added to the simulation box. Energy minimisation, 20‐ns equilibration, and three independent 50‐ns production runs (with initial atom velocities assigned independently and randomly) were performed using GROMACS v.5.1.2 (GROMACS, RRID:SCR_014565; Abraham et al., [2016](#bph14693-bib-0001){ref-type="ref"}) with the charmm36 force field for protein molecules (incorporating CMAP terms, Mackerell, Feig, & Brooks, [2004](#bph14693-bib-0038){ref-type="ref"}) and lipid molecules and salt ions (Best et al., [2012](#bph14693-bib-0005){ref-type="ref"}; Klauda et al., [2010](#bph14693-bib-0030){ref-type="ref"}; MacKerell et al., [1998](#bph14693-bib-0037){ref-type="ref"}). Electrostatics were modelled using particle mesh Ewald (Darden, York, & Pedersen, [1993](#bph14693-bib-0012){ref-type="ref"}), and LINCS was used to constrain covalent chemical bonds to hydrogens (Hess, Bekker, Berendsen, & Fraaije, [1997](#bph14693-bib-0022){ref-type="ref"}). Temperature was maintained at 310 K using velocity rescaling (*V*‐rescale; Bussi, Donadio, & Parrinello, [2007](#bph14693-bib-0008){ref-type="ref"}), and semi‐isotropic pressure coupling was accomplished using the Parrinello--Rahman barostat (Parrinello & Rahman, [1981](#bph14693-bib-0044){ref-type="ref"}). MD trajectories were analysed using VMD v.1.9.2 (VMD, RRID:SCR_001820; Humphrey, Dalke, & Schulten, [1996](#bph14693-bib-0023){ref-type="ref"}) and GROMACS.

2.6. Materials {#bph14693-sec-0014}
--------------

Quinine was purchased from Tocris Bioscience (Bristol, UK) and was diluted in extracellular solution to concentrations indicated in Section [3](#bph14693-sec-0016){ref-type="sec"}. Quinine was applied locally via a glass capillary through a custom‐made application system.

2.7. Nomenclature of targets and ligands {#bph14693-sec-0015}
----------------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., [2018](#bph14693-bib-0020){ref-type="ref"}), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., [2017](#bph14693-bib-0002){ref-type="ref"}).

3. RESULTS {#bph14693-sec-0016}
==========

3.1. Voltage‐independent but mode shift‐dependent inhibition of K~v~12.1 channels through quinine at high concentrations {#bph14693-sec-0017}
------------------------------------------------------------------------------------------------------------------------

We started our pharmacological analyses by applying increasing concentrations of quinine to CHO cells transiently expressing human K~v~12.1. When activating K~v~12.1 with 600‐ms voltage steps to 0 mV from a holding potential of −60 mV, quinine inhibited K~v~12.1 channels with an IC~50~ of 0.97 mM and a Hill coefficient of 1.0 (Figure [1](#bph14693-fig-0001){ref-type="fig"}a). At a concentration close to the IC~50~ (1 mM), this inhibition developed within seconds and was partially reversible after removal of the drug (Figure [S1a,b](#bph14693-supitem-0001){ref-type="supplementary-material"}). After having established the quinine sensitivity of K~v~12.1, we set out to characterise effects of the substance on voltage‐dependent activation of the channels. Noteworthy, K~v~12.1 channels exhibit a mode shift of activation (also termed pre‐pulse facilitation or voltage‐dependent potentiation; Dai & Zagotta, [2017](#bph14693-bib-0011){ref-type="ref"}; Dierich et al., [2018](#bph14693-bib-0013){ref-type="ref"}; Dierich & Leitner, [2018](#bph14693-bib-0014){ref-type="ref"}; Li et al., [2015](#bph14693-bib-0035){ref-type="ref"}), which designates stabilisation of the voltage‐sensing domain in a "relaxed" open state after prolonged depolarisation of the membrane potential (Bezanilla, Taylor, & Fernandez, [1982](#bph14693-bib-0006){ref-type="ref"}; Villalba‐Galea, Sandtner, Starace, & Bezanilla, [2008](#bph14693-bib-0059){ref-type="ref"}). Most prominently, mode shift manifests through a large shift of activation voltages to hyperpolarised potentials following membrane potential depolarisation (Dai & Zagotta, [2017](#bph14693-bib-0011){ref-type="ref"}; Dierich et al., [2018](#bph14693-bib-0013){ref-type="ref"}; Dierich & Leitner, [2018](#bph14693-bib-0014){ref-type="ref"}; Li et al., [2015](#bph14693-bib-0035){ref-type="ref"}). To induce mode shift, we applied conditioning potentials of −60 or 0 mV (200 ms) before a series of voltage steps to activate K~v~12.1 (pulse potentials: −140 to +20 mV; 600 ms; Figure [1](#bph14693-fig-0001){ref-type="fig"}b,c; c.f. Dierich & Leitner, [2018](#bph14693-bib-0014){ref-type="ref"}; Dierich et al., [2018](#bph14693-bib-0013){ref-type="ref"}). Following the hyperpolarised conditioning potential (−60 mV), half‐maximal voltage (*V* ~*h*~) and slope factor of K~v~12.1 channel activation were −30.0 ± 2.0 mV and 14.9 ± 1.1 mV, respectively (*n* = 6; Figure [1](#bph14693-fig-0001){ref-type="fig"}d--f). When we applied the conditioning potential of 0 mV, *V* ~*h*~ was −75.9 ± 1.7 mV and *s* was 10.6 ± 0.5 mV (*n* = 6; Figure [1](#bph14693-fig-0001){ref-type="fig"}d--f). Depolarised conditioning potentials thus induced a large (and significant) shift of the voltages of activation of K~v~12.1 channels to hyperpolarised potentials by about −45 mV, representing their mode shift of activation (Dai & Zagotta, [2017](#bph14693-bib-0011){ref-type="ref"}; Dierich et al., [2018](#bph14693-bib-0013){ref-type="ref"}; Dierich & Leitner, [2018](#bph14693-bib-0014){ref-type="ref"}; Li et al., [2015](#bph14693-bib-0035){ref-type="ref"}). Application of quinine (1 mM) shifted the voltage dependence of K~v~12.1 to depolarised voltages for both conditioning potentials. As this shift was more pronounced after the depolarised conditioning potential (0 mV; Figure [1](#bph14693-fig-0001){ref-type="fig"}d,e), the degree of mode shift was significantly attenuated to about −23 mV in the presence of the substance (Figure [1](#bph14693-fig-0001){ref-type="fig"}e). Application of quinine (1 mM) inhibited both steady‐state currents and tail currents through K~v~12.1 channels (Figure [1](#bph14693-fig-0001){ref-type="fig"}g,h). Following both conditioning potentials, quinine‐induced inhibition of steady‐state K~v~12.1 currents was the same for all activating voltages (Figure [1](#bph14693-fig-0001){ref-type="fig"}i; *n* = 6; e.g., for conditioning potential −60 mV: not significant (*ns*) between −40 mV and +20 mV, *P* = 0.54), that is, quinine inhibited K~v~12.1 channels in a voltage‐independent manner. However, quinine‐dependent block was significantly more pronounced following the hyperpolarised conditioning potential (−60 mV) for activating voltages more positive than −30 mV (indicated by "\*" in Figure [1](#bph14693-fig-0001){ref-type="fig"}i). These data demonstrated that to some extent, K~v~12.1 channels were more sensitive to quinine block after conditioning depolarisation of the membrane, and that accordingly, quinine block of K~v~12.1 channels depended on mode shift.

![Quinine inhibits human K~v~12.1 channels at high concentrations in a voltage‐independent manner. (a) Dose‐dependent inhibition of recombinant K~v~12.1 channels through extracellular application of quinine. The panel shows representative recordings of a CHO cell expressing human K~v~12.1 treated with increasing quinine concentrations (left) and the summarised quinine dose--response relationship (right; IC~50~ and Hill coefficient were calculated from a Hill fit to averaged recordings as shown in the left panel; solid line represents this fit). Scale bars, voltage protocol, quinine concentrations, and number of cells as indicated. (b--f) Quinine induced the activation of recombinant K~v~12.1 channels at more positive membrane potentials. Representative recordings of K~v~12.1 channels activated by voltage steps between −140 and +20 mV following 200‐ms conditioning voltage steps to (b) −60 mV or (c) 0 mV before (control) and at the end of quinine application (1 mM). (d) Summary of voltage‐dependence of K~v~12.1 channels derived from Boltzmann fits to individual recordings as shown in (b, c); solid line represents Boltzmann fit to averaged data. (e) Mean V ~h~ of channel activation and (f) summarised s factors of activation before and at the end of quinine treatment (1 mM; values derived from fits as shown in d). Quinine (1 mM) inhibited voltage‐dependent (g) outward steady‐state and (h) inward tail currents through recombinant K~v~12.1 channels (current amplitudes analysed from recordings as shown in b, c). (i) Quinine‐induced inhibition of K~v~12.1 was voltage‐independent (presented as % inhibition from data shown in (g); ns, no significant difference for quinine block between activating voltages of −40 and 20 mV). Note that quinine block was significantly more pronounced, when K~v~12.1 channels were activated at membrane potentials more positive than −30 mV. \*Significant difference of quinine block for both conditioning potentials](BPH-176-2708-g001){#bph14693-fig-0001}

3.2. Quinine is a voltage‐ and mode shift‐dependent inhibitor of K~v~11.1 channels {#bph14693-sec-0018}
----------------------------------------------------------------------------------

We then compared our findings on K~v~12.1 to quinine‐dependent inhibition of closely related K~v~11.1. In line with a previous study (Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}), quinine inhibited recombinant K~v~11.1 channels with an IC~50~ of 98 μM and a Hill coefficient of 1.3 (Figure [2](#bph14693-fig-0002){ref-type="fig"}a). Accordingly, the quinine affinity of K~v~11.1 channels was about 10 times higher than that of K~v~12.1 (c.f. Figure [1](#bph14693-fig-0001){ref-type="fig"}a). As for K~v~12.1, quinine‐dependent inhibition of K~v~11.1 developed in seconds and was partially reversible (50‐μM quinine; Figure [S1c,d](#bph14693-supitem-0001){ref-type="supplementary-material"}). By applying hyperpolarised (−60 mV) and depolarised (+40 mV) conditioning voltages before the activating pulse potentials, we then analysed effects of quinine on the voltage dependence of K~v~11.1 channels that also exhibit mode shift of activation (Figure [2](#bph14693-fig-0002){ref-type="fig"}b,c). As previously reported (Dierich et al., [2018](#bph14693-bib-0013){ref-type="ref"}; Tan, Perry, Ng, Vandenberg, & Hill, [2012](#bph14693-bib-0055){ref-type="ref"}), depolarised conditioning potentials (+40 mV) significantly shifted the voltage dependence of K~v~11.1 channels by about −50 mV compared with the hyperpolarised conditioning potential (Figure [2](#bph14693-fig-0002){ref-type="fig"}d--f). Following the hyperpolarised conditioning potential (−60 mV), quinine (50 μM) significantly shifted the voltage dependence of K~v~11.1 channels by −13 mV to more negative potentials (Figure [2](#bph14693-fig-0002){ref-type="fig"}d--f). As the voltage dependence of K~v~11.1 was not altered following the depolarised conditioning potential (+40 mV), the degree of mode shift was attenuated in the presence of quinine (50 μM; Figure [2](#bph14693-fig-0002){ref-type="fig"}d,e). Quinine blocked both voltage‐dependent outward and inward currents through K~v~11.1 (Figure [2](#bph14693-fig-0002){ref-type="fig"}g,h). After the conditioning potential of −60 mV, the degree of this inhibition was significantly increased, when the channels were activated at more positive potentials (Figure [2](#bph14693-fig-0002){ref-type="fig"}i), that is, quinine block was voltage dependent following the hyperpolarised conditioning potential. In contrast, following the depolarised conditioning potential, quinine block of K~v~11.1 channels was completely voltage independent. Thus, for K~v~11.1 channels, quinine‐induced inhibition depended on mode shift (c.f. quinidine; Furutani et al., [2011](#bph14693-bib-0018){ref-type="ref"}), but (in contrast to K~v~12.1) the K~v~11.1 channels apparently were more sensitive to quinine following the depolarised conditioning potential, when activated at negative membrane potentials.

![Voltage‐dependent inhibition of K~v~11.1 channels induced by quinine. (a) Quinine inhibited K~v~11.1 channels transiently expressed in CHO cells in a concentration‐dependent manner. The left panel shows representative recordings of a CHO cell expressing K~v~11.1 treated with increasing quinine concentrations, the right panel depicts the summarised quinine dose--response relationship (IC~50~ and Hill coefficient calculated from a Hill fit to averaged data; solid line represents Hill fit). Scale bars, voltage protocol, quinine concentrations, and number of cells recorded as indicated. (b--f) After a conditioning potential of −60 mV, quinine induced activation of recombinant K~v~11.1 channels at more negative membrane potentials. Representative recordings of K~v~11.1 channels activated with voltage steps (as indicated) after conditioning voltage steps to (b) −60 mV or (c) +40 mV before (control) and at the end of the application of quinine (50 μM). (d) Summary of voltage‐dependence of K~v~11.1 channels derived from Boltzmann fits to individual recordings as shown in (b, c); solid line represents Boltzmann fit to averaged data. (e) Mean V ~h~ of channel activation and (f) summarised slope factors of activation before and at the end of quinine application (50 μM; values derived from fits as shown in d). Quinine (1 mM) inhibited voltage‐dependent (g) outward steady‐state and (h) inward tail currents through recombinant K~v~11.1 channels (current amplitudes analysed from recordings as shown in b, c). (i) Quinine‐induced inhibition of K~v~11.1 was voltage‐dependent after conditioning potential of −60 mV but not after the depolarised conditioning potential of +40 mV (presented as % inhibition from data shown in g). \*denotes significant differences](BPH-176-2708-g002){#bph14693-fig-0002}

3.3. Functional characterisation of K~v~12.1(H462Y) channels {#bph14693-sec-0019}
------------------------------------------------------------

Sensitivity of human K~v~11.1 channels to several drugs has been attributed to the amino acids T623, V625, Y652, and F656, located in the channels inner pore helix, selectivity filter, or sixth transmembrane segment (S6; Figure [3](#bph14693-fig-0003){ref-type="fig"}a; Lees‐Miller et al., [2000](#bph14693-bib-0031){ref-type="ref"}; Mitcheson et al., [2000](#bph14693-bib-0040){ref-type="ref"}; Sanchez‐Chapula et al., [2002](#bph14693-bib-0049){ref-type="ref"}; Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}). As K~v~12.1 also carries threonine, valine, and phenylalanine at homologous positions (T433, V435, and F466 in K~v~12.1), we hypothesised that the amino acid exchange at position 462, where K~v~12.1 has a histidine instead of the tyrosine (Figure [3](#bph14693-fig-0003){ref-type="fig"}a), determined the low quinine sensitivity of K~v~12.1. To elaborate this hypothesis, we mutated H462 in K~v~12.1 to the corresponding tyrosine (Y652) of K~v~11.1 and characterised the K~v~12.1(H462Y) mutant in CHO cells. Recombinant K~v~12.1(H462Y) channels produced robust voltage‐dependent and outwardly rectifying K^+^ currents (Figure [3](#bph14693-fig-0003){ref-type="fig"}b,c). However, K~v~12.1(H462Y)‐mediated whole‐cell currents were significantly smaller than for the wild‐type channels (Figure [3](#bph14693-fig-0003){ref-type="fig"}b--d), and the mutant channels activated significantly faster than the wild‐type, when activated through voltage steps between −40 and 0 mV (Figure [3](#bph14693-fig-0003){ref-type="fig"}e). For conditioning voltages of −60 and 0 mV, *V* ~*h*~ was −38.0 ± 1.8 mV and −73.6 ± 1.6 mV, respectively, demonstrating that K~v~12.1(H462Y) channels also exhibited a mode shift of activation (Figure [3](#bph14693-fig-0003){ref-type="fig"}f--h; *n* = 9). However, in the mutant, mode shift was attenuated compared with wild‐type to about −35 mV (−45 mV in wild‐type; c.f. Figure [1](#bph14693-fig-0001){ref-type="fig"}), mainly because K~v~12.1(H462Y) activated at significantly more negative membrane potentials after the hyperpolarised conditioning potential of −60 mV (Figure [3](#bph14693-fig-0003){ref-type="fig"}f--h). The voltage dependence of wild‐type and mutant channels was the same after the conditioning potential of 0 mV (Figure [3](#bph14693-fig-0003){ref-type="fig"}f--h).

![Characteristics of the K~v~12.1(H462Y) channel mutant. (a) The panel shows an alignment of K~v~11.1 isoforms from humans and rats (encoded by the KCNH2 gene) with human K~v~12.1 channels (KCNH8 gene). Amino acids recently identified as important for quinoline‐dependent inhibition of K~v~11.1 channels are highlighted in colour (green, identical amino acids; red, amino acid exchange in K~v~12.1; see text for details and references). Note that the quinine‐binding "motif" of K~v~12.1 differs only at one position from K~v~11.1 channels. (b--h) Biophysical characteristics of K~v~12.1(H462Y; red) in comparison with K~v~12.1 wild‐type channels (black). (b, c) Representative recordings of currents through K~v~12.1 wild‐type (black) and K~v~12.1(H462Y; red) channels activated with the shown voltage protocols. (d) Steady‐state outward currents through K~v~12.1(H462Y) were significantly smaller than through K~v~12.1 wild‐type channels, and (e) K~v~12.1(H462Y) activated significantly faster than wild‐type channels, when activated through voltage steps between −40 and 0 mV (τ derived from monoexponential fits to activating current components in recordings shown in b, c). (f--h) K~v~12.1(H462Y) activated at significantly more negative membrane potentials than wild‐type channels after conditioning potential of −60 mV. (f) Summary of voltage‐dependence of K~v~12.1(H462Y) channels derived from Boltzmann fits to individual recordings as shown in (b, c); solid line represents Boltzmann fit to averaged data. (g) Mean V ~h~ of channel activation and (h) summarised slope factors of activation (data on K~v~12.1 wild‐type channels are reproduced from Figure [1](#bph14693-fig-0001){ref-type="fig"}). \*denotes significant differences](BPH-176-2708-g003){#bph14693-fig-0003}

3.4. Histidine at position 462 determines the quinine sensitivity of human K~v~12.1 {#bph14693-sec-0020}
-----------------------------------------------------------------------------------

When applying increasing quinine concentrations to CHO cells expressing K~v~12.1(H462Y), we found that quinine inhibited this channel mutant with an IC~50~ of 56 μM and a Hill coefficient of 1.1 (Figure [4](#bph14693-fig-0004){ref-type="fig"}a). Thus, the quinine affinity of K~v~12.1(H462Y) was about 17‐fold higher than that of the wild‐type channels and accordingly more similar to K~v~11.1 (c.f. Figures [1](#bph14693-fig-0001){ref-type="fig"}a and [2](#bph14693-fig-0002){ref-type="fig"}a). As for K~v~12.1 wild‐type, application of quinine (50 μM) blocked inward and outward currents through K~v~12.1(H462Y) (Figure [4](#bph14693-fig-0004){ref-type="fig"}b--e), but in contrast to the wild‐type channels, quinine‐mediated inhibition of K~v~12.1(H462Y) was rapidly reversible (Figure [S1e,f](#bph14693-supitem-0001){ref-type="supplementary-material"}). Noteworthy, we detected a transient increase of currents in the presence of quinine, when activating K~v~12.1(H462Y) at membrane voltages more positive than 0 mV (following the hyperpolarised conditioning potential; Figure [4](#bph14693-fig-0004){ref-type="fig"}b). This observation indicated that channel opening may be required for quinine‐dependent inhibition of K~v~12.1(H462Y). In line, quinine‐induced inhibition of K~v~12.1(H462Y) was more pronounced, when the channels where activated at more positive membrane voltages, that is, quinine block of K~v~12.1(H462Y) was voltage dependent following positive and negative conditioning potentials (Figure [4](#bph14693-fig-0004){ref-type="fig"}f). For K~v~12.1(H462Y) channels, this voltage dependence of quinine block presumably also caused a reduction of tail currents at depolarised activating voltages after conditioning potential of 0 mV (Figure [4](#bph14693-fig-0004){ref-type="fig"}e,g). Of special note, in contrast to K~v~12.1 wild‐type channels, quinine block of K~v~12.1(H462Y) was the same following both conditioning potentials and thus was independent on mode shift. Contrary to K~v~12.1 wild‐type, quinine (50 μM) shifted the voltage dependence of K~v~12.1(H462Y) by −11 mV and −10 mV to hyperpolarised potentials after conditioning voltages of −60 mV and 0 mV respectively (Figure [4](#bph14693-fig-0004){ref-type="fig"}g--i).

![Voltage‐dependent inhibition of K~v~12.1(H462Y) channels through quinine at low concentrations. (a) Extracellular application of quinine inhibited K~v~12.1(H462Y) channels overexpressed in CHO cells. The panel shows representative recordings of a CHO cell expressing K~v~12.1(H462Y) treated with increasing quinine concentrations (left) and the summarised dose--response relationship (right; IC~50~ and Hill coefficient were calculated from a Hill fit to averaged recordings as shown in the left panel; solid line represents Hill fit). Scale bars, voltage protocol, quinine concentrations, and number or cells recorded as indicated. (b--i) Quinine inhibited inward and outward currents through K~v~12.1(H462Y) channels and induced channel activation at more negative membrane potentials. Representative recordings of recombinant K~v~12.1 channels activated by voltage steps between −140 and +20 mV following 200‐ms conditioning voltage steps to (b) −60 mV or (c) 0 mV before (black) and at the end of quinine application (50 μM; red). Summarised voltage‐dependent (d) steady‐state currents and (e) inward tail currents through K~v~12.1(H462Y) before (black) and at the end of quinine treatment (50 μM; current amplitudes analysed from recordings as shown in b, c). (f) Quinine‐induced inhibition of K~v~12.1(H462Y) was voltage‐dependent (presented as % inhibition from data shown in d). (g--i) Summary of voltage‐dependence of K~v~12.1(H462Y) channels derived from Boltzmann fits to individual recordings as shown in (b, c); solid line represents Boltzmann fit to averaged data. (h) Mean V ~h~ of channel activation and (i) summarised slope factors of activation before and at the end of treatment with quinine (50 μM; values derived from fits as shown in g). \*denotes significant differences](BPH-176-2708-g004){#bph14693-fig-0004}

3.5. K~v~12.1(H462Y) channels exhibit K~v~11.1‐like quinine sensitivity {#bph14693-sec-0021}
-----------------------------------------------------------------------

In summary, K~v~12.1(H462Y) exhibited a 17 times higher quinine affinity than K~v~12.1 wild‐type, that is, quinine sensitivity of K~v~12.1(H462Y) was more similar to K~v~11.1 than to the wild‐type channels (Figure [5](#bph14693-fig-0005){ref-type="fig"}a). Application of quinine induced opening of wild‐type K~v~12.1 channels at more positive potentials but at more negative values for K~v~12.1(H462Y) and K~v~11.1 (Figure [5](#bph14693-fig-0005){ref-type="fig"}b). Quinine inhibited K~v~12.1 channels in a voltage‐independent manner, but quinine block was completely voltage dependent for K~v~12.1(H462Y) and partially voltage dependent (after hyperpolarised conditioning potentials) for K~v~11.1 channels (Figure [5](#bph14693-fig-0005){ref-type="fig"}c,d). In contrast to K~v~12.1(H462Y), K~v~12.1 wild‐type channels apparently were more sensitive to quinine after conditioning hyperpolarisation of the membrane (c.f. Figure [1](#bph14693-fig-0001){ref-type="fig"}i), that is, for K~v~12.1 wild‐type channels, quinine‐induced inhibition depended on mode shift (just as for K~v~11.1 channels). Accordingly, closely related K~v~12.1 and K~v~11.1 channels exhibited markedly different quinine sensitivity and characteristics of inhibition, but introduction of the H462Y amino acid exchange conferred K~v~11.1‐like quinine sensitivity to K~v~12.1 channels. Based on these findings, we conclude that H462 determines the low quinine sensitivity and the characteristics of quinine‐dependent inhibition for K~v~12.1 channels and that the binding pocket for substituted quinolines in the central cavity is not completely conserved within the Eag superfamily of K~v~ channels. However, as the H462Y point mutation restored K~v~11.1‐like quinine sensitivity in K~v~12.1, these findings demonstrated that the quinoline‐binding pocket also exists in K~v~12.1 and that thus the overall architecture of the channels is similar.

![The inhibition induced by quinine of K~v~12.1(H462Y) channels shows K~v~11.1‐like characteristics. This figure summarises our findings on K~v~12.1 wild‐type channels and H462Y mutant as well as on K~v~11.1 wild‐type channels (data are reproduced from Figures [1](#bph14693-fig-0001){ref-type="fig"}, [2](#bph14693-fig-0002){ref-type="fig"}, [3](#bph14693-fig-0003){ref-type="fig"}, [4](#bph14693-fig-0004){ref-type="fig"}). (a) The affinity of K~v~12.1(H462Y) for quinine was 17‐fold higher than that of the wild‐type and accordingly very similar to K~v~11.1. (b) Quinine induced activation of K~v~12.1 channels at more positive potentials following the hyperpolarised (−60 mV) and the depolarised conditioning potential (0 mV). In contrast, K~v~12.1(H462Y) and K~v~11.1 channels activated at more negative membrane potentials in the presence of quinine following the hyperpolarised conditioning potential. Only slight changes of voltage‐dependence of K~v~12.1(H462Y) and K~v~11.1 channels were detected during application of quinine following the depolarised conditioning potential. (c, d) Quinine‐mediated block was voltage‐independent for K~v~12.1 but voltage‐dependent for K~v~12.1(H462Y). Note that quinine inhibition of K~v~11.1 channels was voltage‐dependent only following the hyperpolarised conditioning potential. Summaries of quinine‐induced inhibition (% of controls) for (c) the hyperpolarised and for (d) the depolarised conditioning membrane potential. Quinine was applied at 1 mM for K~v~12.1 channels and at 50 μM for K~v~12.1(H462Y) and K~v~11.1. Mode shift was induced through conditioning potentials of −60 and 0 mV for K~v~12.1 isoforms and at −60 and +40 mV for K~v~11.1 channels](BPH-176-2708-g005){#bph14693-fig-0005}

3.6. H462 determines the low quinine affinity of human K~v~12.1 channels {#bph14693-sec-0022}
------------------------------------------------------------------------

To elucidate the molecular principles of the low quinine affinity of K~v~12.1, we performed molecular docking and subsequent MD analyses (Figure [6](#bph14693-fig-0006){ref-type="fig"}). Quinine binding to the pore helix/S6 domain (amino acids S353--Y477) of K~v~12.1 and K~v~12.1(H462Y) channels was studied using homology models based on the cryo‐EM structure of human K~v~11.1 (Wang & MacKinnon, [2017](#bph14693-bib-0060){ref-type="ref"}). We also utilised the available structural information to study quinine binding to K~v~11.1 channels. Molecular docking suggested that quinine binds below residue H462 into the central cavity of human K~v~12.1 (Figure [6](#bph14693-fig-0006){ref-type="fig"}a, left panel), with an estimated binding affinity (Chemscore.DG) of −20.5 kJ·mol^−1^. To validate the stability and refine the binding pose obtained from docking, we performed three independent 50‐ns MD simulations of the highest scored docking pose. Overall, quinine remained stable in these MD simulations, as indicated by root‐mean‐square deviation (RMSD) below 2 Å (Figure [6](#bph14693-fig-0006){ref-type="fig"}d, left panel). Further, π--π stacking between methoxyquinoline group and H462 from one subunit was maintained throughout 50 ns of MD simulation (Figure [6](#bph14693-fig-0006){ref-type="fig"}b,c, left panel). Similar to wild‐type channels, quinine docked into the central cavity of K~v~12.1(H462Y) without any obvious interactions to the residues of the selectivity filter (Figure [6](#bph14693-fig-0006){ref-type="fig"}a--c, middle panel). In K~v~12.1(H462Y), π--π interactions with the methoxyquinoline moiety were also observed; however, in the mutant channel, these interactions are formed with mutated Y462 side chains from two adjacent subunits. Additionally, we observed a hydrogen bond between Y462 and quinoline moiety of quinine in the majority of docking poses that remained stable throughout the 50‐ns MD simulations. In agreement with our experimental findings, the estimated quinine‐binding affinity of −31.1 kJ·mol^−1^ for K~v~12.1(H462Y) was considerably higher than for wild‐type K~v~12.1 channels. In line, in the simulations, an additional hydrogen bond between the methoxy group of quinidine and the residue T470 formed in the mutant channels (Figure [6](#bph14693-fig-0006){ref-type="fig"}c, middle panel). As shown in Figure [6](#bph14693-fig-0006){ref-type="fig"}d, the binding pose of quinine was highly stable in MD simulations, with an RMSD of about 1 Å. In the K~v~11.1 cryo‐EM structure (Wang & MacKinnon, [2017](#bph14693-bib-0060){ref-type="ref"}), quinine was also predicted to bind slightly below Y652, in the central cavity, with favourable hydrophobic interactions with Y652 residues of all subunits and with F656 from only one subunit. Also, in line with our experimental findings, the estimated affinity of quinine binding to K~v~11.1 wild‐type channels amounts to −33.9 kJ·mol^−1^ in our simulations and thus was similar to K~v~12.1(H462Y) and higher than that of wild‐type K~v~12.1 channels. Further, π--π interactions with Y652 and F656 residues in K~v~11.1 from opposite subunits were predicted by these simulations (Figure [6](#bph14693-fig-0006){ref-type="fig"}b,c, right panel), again leading to a very stable binding mode with RMSD values of \~1 Å (Figure [6](#bph14693-fig-0006){ref-type="fig"}d, right panel).

![Molecular interactions of quinine with K~v~12.1, K~v~12.1(H462Y), and K~v~11.1. (a) Top‐view representations of K~v~12.1 (left), K~v~12.1(H462Y; middle), and K~v~11.1 (right) channels with docked quinine (green--cyan spheres). (b) Top and (c) side view of the quinine‐binding site after 50 ns of molecular dynamics simulations for K~v~12.1 (left), K~v~12.1(H462Y; middle), and K~v~11.1 (right). Directly interacting residues, as well as position 462 in K~v~12.1 isoforms (652 in K~v~11.1), are presented as sticks, with oxygen atoms coloured in red and nitrogen atoms coloured in blue. Yellow lines indicate π‐stacking interactions, while red lines indicate H bonds. (d) Stability of the pore domains (excluding extracellular loops), measured as the root‐mean‐square deviation (RMSD) as a function of 50‐ns simulation time](BPH-176-2708-g006){#bph14693-fig-0006}

In summary, molecular modelling revealed that weak interactions between quinine and particularly H462 determined the low affinity and sensitivity of K~v~12.1 wild‐type channels to quinine. The higher affinity of K~v~12.1(H462Y) channels and of the closely related K~v~11.1 can be explained by more favourable interactions with the drug, mainly at position Y462, and in the case of K~v~11.1 additionally with F656 from one subunit. Surprisingly, despite the conservation of this second aromatic side chain between K~v~11 and K~v~12 channels, interactions with this second aromatic residue are completely absent in the K~v~12.1 (Figure [6](#bph14693-fig-0006){ref-type="fig"}b, left panel vs. right panel). However, also in K~v~11.1 channels, these interactions are relatively weak due to a preferred orientation of the Y652/F656 side chains towards helix S5 (see Figure [S2](#bph14693-supitem-0001){ref-type="supplementary-material"}, for orientation of aromatic side chains at positions H462/F466 in K~v~12.1 wild‐type and Y652/F656 in K~v~11.1 wild‐type channels in simulations).

4. DISCUSSION {#bph14693-sec-0023}
=============

Substituted quinolines are well‐known antimalarial agents (quinine and chloroquine) and antiarrhythmic drugs (quinidine; Bozic, Uzelac, Kezic, & Bajcetic, [2018](#bph14693-bib-0007){ref-type="ref"}). As considerable side effect, these substances inhibit K~v~11.1 channels at low micromolar concentrations, which may result in acquired (drug‐induced) LQT syndrome, syncope, and sudden death in humans (Mitcheson et al., [2005](#bph14693-bib-0039){ref-type="ref"}; Mitcheson et al., [2000](#bph14693-bib-0040){ref-type="ref"}; Sanguinetti & Tristani‐Firouzi, [2006](#bph14693-bib-0051){ref-type="ref"}). Several mutagenesis studies have attributed the susceptibility of K~v~11.1 to drug‐dependent block to amino acids in the pore domain of these channels, threonine 623 and valine 625 of inner pore helix and selectivity filter, respectively, as well as tyrosine 652 and phenylalanine 656 in the sixth transmembrane segment (S6; Mitcheson et al., [2000](#bph14693-bib-0040){ref-type="ref"}; Sanchez‐Chapula et al., [2002](#bph14693-bib-0049){ref-type="ref"}; Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}). On the one hand, valine 625 (together with other residues such as asparagine 588, serine 631, and serine 620) controls drug sensitivity of K~v~11.1 through its contribution to channel inactivation that has been shown to be necessary for channel inhibition by several high‐affinity blockers (e.g., Kamiya et al., [2006](#bph14693-bib-0027){ref-type="ref"}; Perrin et al., [2008](#bph14693-bib-0045){ref-type="ref"}; Wu et al., [2015](#bph14693-bib-0061){ref-type="ref"}). On the other hand, some of these residues form hydrophobic pockets in combination with other amino acids at the inner surface of the small central cavity of K~v~11.1 channels (Wang & MacKinnon, [2017](#bph14693-bib-0060){ref-type="ref"}). These pockets are endowed with high electronegative potentials and therefore favour binding of positively charged drugs (Wang & MacKinnon, [2017](#bph14693-bib-0060){ref-type="ref"}). The exclusive sensitivity of K~v~11.1 to a wide variety of drugs with diverging structures is explained by the absence of such binding pockets in other K^+^ channels (Wang & MacKinnon, [2017](#bph14693-bib-0060){ref-type="ref"}).

Closely related K~v~10 and K~v~12 channels share high similarity to K~v~11.1, which suggests that these channels also possess analogous drug‐binding pockets, similar drug sensitivity, and characteristics of inhibition (Bauer & Schwarz, [2018](#bph14693-bib-0004){ref-type="ref"}). Indeed, the respective amino acids determining the susceptibility of K~v~11.1 to quinoline block are conserved in K~v~10 channels. However, whereas K~v~10.1 displayed the same sensitivity to quinidine‐dependent inhibition as K~v~11.1, quinidine sensitivity of K~v~10.2 channels was 100‐fold lower (Gessner et al., [2004](#bph14693-bib-0019){ref-type="ref"}; Lees‐Miller et al., [2000](#bph14693-bib-0031){ref-type="ref"}; Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}; Schonherr et al., [2002](#bph14693-bib-0053){ref-type="ref"}). The lower susceptibility of the K~v~10 isoforms to drug‐induced inhibition is explained by their lack of inactivation, that is, conformational reorientations during inactivation necessary for high affinity drug block in K~v~11.1 do not occur in K~v~10 channels (Chen et al., [2002](#bph14693-bib-0009){ref-type="ref"}; Ficker et al., [1998](#bph14693-bib-0017){ref-type="ref"}; Ficker et al., [2001](#bph14693-bib-0016){ref-type="ref"}). Thus, the lower sensitivity of K~v~10 channels indicates that additional drug interaction sites outside the central binding motif might determine drug block in these channels (Gessner et al., [2004](#bph14693-bib-0019){ref-type="ref"}; Schonherr et al., [2002](#bph14693-bib-0053){ref-type="ref"}). We wondered whether K~v~12.1 channels possess a quinoline‐binding pocket analogous to K~v~10.1 and K~v~11.1 channels despite an amino acid exchange at position 462. We found that quinine inhibited K~v~12.1 channels, but their sensitivity was 10 times lower than that of K~v~11.1 channels. Thus, K~v~12.1 constitutes a natural variant of Eag superfamily channels with low quinoline‐binding affinity.

4.1. H462 determines quinine sensitivity of K~v~12.1 {#bph14693-sec-0024}
----------------------------------------------------

The quinoline‐binding "motif" of K~v~11.1 is not completely conserved in the three members of the K~v~12 channel family that carry a histidine at the position homologous to tyrosine 652 in K~v~11.1 (H462 in K~v~12.1; c.f. Figure [3](#bph14693-fig-0003){ref-type="fig"}a). As in K~v~11.1, this aromatic residue determines the quinoline‐binding affinity (Lees‐Miller et al., [2000](#bph14693-bib-0031){ref-type="ref"}; Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}), we hypothesised that this small sequence difference explained the 10‐fold lower quinine sensitivity of K~v~12.1. Indeed, replacing this histidine in K~v~12.1 with the respective tyrosine of K~v~11.1 through site‐directed mutagenesis dramatically increased the quinine affinity of K~v~12.1(H462Y). In fact, quinine sensitivity of K~v~12.1(H462Y) was more similar to K~v~11.1 than to wild‐type K~v~12.1. Our findings are supported by earlier studies showing that mutating Y652 dramatically changes quinidine sensitivity of K~v~11.1 channels, for example, introduction of an alanine at this position caused a threefold reduction of quinidine affinity in K~v~11.1(Y652A) channels (Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}). Utilising molecular modelling simulations, we found that the low sensitivity of K~v~12.1 channels may be explained by only weak interactions between quinine and amino acids in the central cavity (including H462). Noteworthy, in K~v~12.1(H462Y) channels, more favourable interactions developed that most probably rendered this channel mutant more sensitive to quinine. In line with our experimental findings, docking analyses predicted considerably lower quinine affinities for K~v~12.1 (−20.5 kJ·mol^−1^), compared with the K~v~12.1(H462Y) mutant (−31.1 kJ·mol^−1^) and K~v~11.1 wild‐type channels (−33.9 kJ·mol^−1^). Our models predicted a key difference in the orientation and interactions of the first aromatic side chain, which limits hydrophobic and π--π interactions in K~v~12, while providing strong interactions in K~v~11 channels. Taking together, our findings are in good agreement with a hypothesis previously published by the Sanguinetti group (Chen et al., [2002](#bph14693-bib-0009){ref-type="ref"}). Thus, our modelling approach recapitulated experimental findings on K~v~11.1 (Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}) and provided a ready and straightforward explanation for the higher quinine affinity of K~v~11.1 and K~v~12.1(H462Y) compared with K~v~12.1 wild‐type channels.

Yet, as mentioned above, drug sensitivity of K~v~11.1 channels is determined by channel inactivation (e.g., through V625, N588, S631, and S620; Ficker et al., [1998](#bph14693-bib-0017){ref-type="ref"}; Ficker et al., [2001](#bph14693-bib-0016){ref-type="ref"}; Kamiya et al., [2006](#bph14693-bib-0027){ref-type="ref"}; Perrin et al., [2008](#bph14693-bib-0045){ref-type="ref"}; Wu et al., [2015](#bph14693-bib-0061){ref-type="ref"}). As shown for K~v~10 channels (Chen et al., [2002](#bph14693-bib-0009){ref-type="ref"}; Ficker et al., [1998](#bph14693-bib-0017){ref-type="ref"}; Ficker et al., [2001](#bph14693-bib-0016){ref-type="ref"}), lack of inactivation might contribute to low drug sensitivity of K~v~12.1 channels. However, above‐mentioned residues (except N588 where K~v~12.1 has an E) are conserved in K~v~12.1 channels, and the single amino acid exchange H462Y sufficed to significantly lower the quinine affinity of these channels (even slightly below that of K~v~11.1 channels; c.f. Figure [5](#bph14693-fig-0005){ref-type="fig"}a). We thus estimate that relevance of these amino acids for drug interactions is low in K~v~12.1, but we cannot provide any evidence for this assumption at present. Thus, further work is needed to elucidate whether these residues also determine drug sensitivity in K~v~12 family members and whether the channel mutant inactivates at all (e.g., during prolonged depolarisations).

Importantly, our findings once again highlight that Y652 determines quinoline sensitivity in closely related K~v~11.1 channels (Lees‐Miller et al., [2000](#bph14693-bib-0031){ref-type="ref"}; Macdonald, Kim, Kurata, & Fedida, [2018](#bph14693-bib-0036){ref-type="ref"}; Sanchez‐Chapula et al., [2002](#bph14693-bib-0049){ref-type="ref"}; Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}). Although indicated by an early report analysing binding of chloroquine to K~v~11.1 in silico (Sanchez‐Chapula et al., [2002](#bph14693-bib-0049){ref-type="ref"}), we did not detect any cation--π interactions between quinine and K~v~11.1, K~v~12.1, or K~v~12.1(H462Y) channels. Noteworthy, our simulations support a recent study that utilised unnatural amino acid incorporation to show that cation--π interactions at position Y652 are not relevant for drug binding in K~v~11.1 channels (Macdonald et al., [2018](#bph14693-bib-0036){ref-type="ref"}). Based on these findings, we conclude that H462 determines the low quinine sensitivity of K~v~12.1 and that possibly no amino acid motifs outside the central cavity contribute to quinoline binding in K~v~12.1 channels (for K~v~10, see Gessner et al., [2004](#bph14693-bib-0019){ref-type="ref"}; Schonherr et al., [2002](#bph14693-bib-0053){ref-type="ref"}). Thus, as far as quinoline sensitivity is concerned, K~v~12 channels are probably more similar to other K~v~ families that typically carry isoleucine or valine at this position than to closely related K~v~11 channels.

4.2. H462 determines characteristics of quinine‐dependent inhibition in K~v~12.1 {#bph14693-sec-0025}
--------------------------------------------------------------------------------

Our experiments showed that quinine‐induced inhibition of K~v~12.1 channels was largely voltage independent and characterised by a shift of activation voltages to depolarised potentials. Although it has been shown that many inhibitors (including quinidine or chloroquine; Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}; Sanchez‐Chapula et al., [2002](#bph14693-bib-0049){ref-type="ref"}) preferentially block activated K~v~11.1 channels, we did not find any evidence for such quinine‐dependent open channel block for K~v~12.1 wild‐type channels. Transient activation of K~v~12.1(H462Y) channels at depolarised membrane potentials in the presence of quinine (c.f. Figure [4](#bph14693-fig-0004){ref-type="fig"}b), however, might indicate such open channel block for the channel mutant, but we consider that further work including other inhibitors is needed to elucidate whether the amino acid position 462 indeed determines open channel block in K~v~12.1 channels.

As K~v~12.1 wild‐type channels were more sensitive to quinine after conditioning hyperpolarisation of the membrane, quinine block depended on mode shift, in contrast to K~v~12.1(H462Y) that were inhibited by quinine independent on conditioning potentials. Although we do not have any evidence for this assumption yet, conformational changes associated with establishment of mode shift might thus render K~v~12.1 channels less sensitive to quinine. Quinine inhibited K~v~11.1 more significantly, when the channels were activated at depolarised potentials, but only following the hyperpolarised conditioning potential. Thus, quinine block of K~v~11.1 also depended on mode shift, but the underlying mechanisms may be different between K~v~11 and K~v~12 channels. In contrast to K~v~12.1 wild‐type channels, quinine induced K~v~11.1 channel opening at more negative membrane potentials in line with a previous report (Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}). Interestingly, the H462Y amino acid exchange conferred K~v~11.1‐type characteristics of quinine‐dependent inhibition to K~v~12.1 channels. Thus, H462 determines not only quinine sensitivity but also the characteristics of quinine‐dependent inhibition in K~v~12.1 channels. Likewise, mutating the homologous tyrosine substantially changed the voltage dependence of quinoline block in K~v~11.1, that is, voltage dependence was abolished in K~v~11.1(Y652F), but it was completely reversed in K~v~11.1(Y652A) channels (Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}). Yet the molecular mechanisms underlying such voltage‐dependent inhibition remain elusive for the K~v~12.1 mutant, as well as for K~v~11.1 channels. It was hypothesised earlier for chloroquine‐induced block of K~v~11.1 that Y652 might change position during voltage‐dependent gating, thereby generating a depolarisation‐induced binding pocket with higher affinity (Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}). This may induce pronounced channel inhibition during channel activation at more depolarised membrane potentials. Accordingly, as proposed for K~v~11.1 carrying mutations at position 652 (Sanchez‐Chapula et al., [2003](#bph14693-bib-0048){ref-type="ref"}), the low quinine affinity of K~v~12.1 wild‐type channels might prevent generation of an analogous binding site with higher affinity, which might account for lack of voltage dependence in these channels. Thus, similar molecular mechanisms may apply for K~v~11.1 and K~v~12.1 during drug‐induced inhibition, but we cannot provide any evidence for such processes at present.

4.3. Conclusion and significance {#bph14693-sec-0026}
--------------------------------

We showed that K~v~12.1 is a natural variant of Eag superfamily channels with low quinine sensitivity. Thus, the drug‐binding pocket in the central cavity is not completely conserved in the Eag superfamily of K~v~ channels, which highlights functional and pharmacological diversity within this group of evolutionary conserved ion channels. However, our work also demonstrated that the drug‐binding pocket exists in K~v~12.1 and that thus the overall architecture of the channels is similar. Further work is needed to elucidate whether K~v~12.1 channels are also endowed with lower sensitivity to the many more drugs that block closely related K~v~11.1.
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Figure S1. **Rapid inhibition of recombinant K** ~**v**~ **12.1, K** ~**v**~ **11.1 and K** ~**v**~ **12.1(H462Y) channels through quinine. (A,C,E)** Within seconds, application of quinine inhibited currents through (A) K~v~12.1, (C) K~v~11.1 and (E) K~v~12.1(H462Y) channels transiently overexpressed in CHO cells. The left panels show representative recordings of CHO cells expressing these channel subunits before application of quinine (control; black), at the end of quinine treatment (red) and several minutes after wash‐out of the substance (grey). The right panels show analyses of the time course of current amplitudes recorded in these experiments upon application of quinine. Data are presented as normalised to base line current amplitudes (I/I~control~). **(B,D,F)** In the same cells, application of quinine induced reversible depolarisation of the membrane potential. All voltage‐protocols, scale bars, quinine concentrations and time points after wash‐out as indicated.

**Figure S2. Molecular dynamics of residues H462/F466 in (K** ~**v**~ **12.1 and K** ~**v**~ **12.1(H462Y)) and Y652/F656 (in K** ~**v**~ **11.1).** Top view of superposed snapshots from 3 independent 50 ns molecular dynamics simulations of residues H462/F466 in K~v~12.1 wt (left column) and K~v~12.1(H462Y) (middle column) and of corresponding residues Y652/F656 in K~v~11.1 wt channels (right column).
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